Fig. 4: CDK4/6 inhibition associates with increased response to PD-L1 blockade.
From: Molecular determinants of response to PD-L1 blockade across tumor types
a Volcano plot representing the genes differentially expressed between responders and nonresponders. The gene-level linear model contrasts responders (CR/PR) and nonresponders (SD/PD), including indication and PD-L1 expression as covariates. Genes significantly upregulated or downregulated after Benjamini–Hochberg correction (p < 0.1) and absolute log2 fold change ≥  0.5 are colored in red and blue, respectively. b Horizontal bar chart representing the percent of patients exhibiting partial (CN1) or complete copy-number deletion (CN0) of the CDKN2A locus across the Foundation Medicine database (n = 97,811 after QC) for selected indications. The ratio and percentage of patients with CDKN2A loss within each ontology is represented on the right of each bar. c Response rate by CDKN2A deletion status. Bar charts represent the proportion of responders to nonresponders by CDKN2A deletion status (no DEL: copy-number ≥ 2; DEL: copy-number < 2). P values were calculated using the two-sided Pearson’s chi-squared test. d Overall survival (OS) for mUC and NSCLC cohorts and progression-free survival (PFS) for the RCC cohort, split by transcriptional expression of CDKN2A (top) or CDK6 (bottom). Transcription level is defined as high (≥median, red) or low (<median, blue) within each indication.
